Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Receives Consensus Rating of “Buy” from Brokerages

·

·

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Receives Consensus Rating of “Buy” from Brokerages

Inovio Pharmaceuticals logo Shares of Inovio Pharmaceuticals, Inc. (NASDAQ:INO) have been given an average rating of “Buy” by the twelve ratings firms that are currently covering the company, Marketbeat reports.
See Original Article

Accounting for Temporary Differences in Taxable Income

Prerequisite: Exposure to accounting for income taxes; Advanced Preparation: None. Description. Although a majority of income and deduction items
See Original Article

You Could Buy 100 Boxes of Avocados for the Price of One Bitcoin

Even with all the hand-wringing about bubbles in stock and bond markets, it's hard to ignore what's going on in the world of cryptocurrencies and
See Original Article

Valeant's Top Drug Is Growing Again, Offsetting Wider Slump

Valeant Pharmaceuticals International Inc.'s most important drug is showing signs of getting back on track, offsetting declining sales elsewhere as the
See Original Article

Zuma Survives No-Confidence Vote to Maintain Grip on Power

South African President Jacob Zuma survived a vote of no-confidence in Parliament in Cape Town on Tuesday. (Source: Bloomberg). South African
See Original Article



Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.